| KAI Pharma initiates phase 1b study of KAI-4169 for secondary ... - pharmabiz.com |
|
|
pharmabiz.comMineral and bone disorders can be devastating to the health of ESRD patients with SHPT. KAI is committed to addressing this compelling medical need. ... read more |